Asset Details
Do you wish to reserve the book?
The Impact of Clinical Pharmacist Consultation on the Treatment of Multi- Drug Resistant Organisms
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Impact of Clinical Pharmacist Consultation on the Treatment of Multi- Drug Resistant Organisms
Do you wish to request the book?
The Impact of Clinical Pharmacist Consultation on the Treatment of Multi- Drug Resistant Organisms
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Impact of Clinical Pharmacist Consultation on the Treatment of Multi- Drug Resistant Organisms
2025
Overview
Purpose: Multidrug-resistant organisms (MDROs) infections are associated with high mortality in hospitalized patients. Clinical pharmacists play a crucial role in optimizing anti-infection treatment strategies. This study aimed to evaluate the impact of clinical pharmacist consultation on the treatment of inpatients with MDRO infections. Methods: Patients infected with MDROs who received clinical pharmacist consultation between June 2020 and June 2023 were enrolled. The adoption rate and effectiveness rate of consultation were calculated. Univariate and multivariate logistic regression analyses were conducted to identify factors influencing the effectiveness rate of consultation. Cox regression analysis was employed to estimate the 30-day survival rate post-consultation for patients infected with MDROs, comparing those who adopting pharmacists' suggestions with those who did not. Results: A total of 620 patients were included. More patients were from the surgical system, especially neurosurgery. The top 3 infection sites were respiratory tract, urinary tract and blood, with prevalent MDROs including Carbapenem-resistant Klebsiella pneumoniae (CRKP), Carbapenem-resistant Acinetobacter baumannii (CRAB), and Carbapenem-resistant Pseudomonas aeruginosa (CRPA). Following the implementation of consultation recommendations, patients exhibited significant reductions in temperatures, inflammatory markers, and Sequential Organ Failure Assessment (SOFA) scores. The adoption and effectiveness rate of consultation were 89.67% and 58.71%, respectively. Multivariate analysis showed that there were significant association of liver dysfunction (adjusted OR = 0.331, 95% CI: 0.217-0.504), severity of infection (adjusted OR = 0.292, 95% CI: 0.151-0.562) and adopting pharmacists' suggestions (adjusted OR = 1.987, 95% CI: 1.126-3.507) with the effectiveness rate of consultation. Cox regression analysis revealed a significant difference in the 30-day survival rate between MDRO patients who received pharmacist recommendations and those who did not (HR = 0.422, 95% CI: 0.185-0.963, P = 0.04). Conclusion: Our research indicated that the involvement of clinical pharmacists could be advantageous for patients afflicted with MDRO infections. Keywords: multidrug-resistant organisms, infectious diseases, clinical pharmacists, consultations
Publisher
Dove Medical Press Limited
Subject
